- Valdecoxib
drugbox
IUPAC_name = 4-(5-methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
width = 174
CAS_number = 181695-72-7
ATC_prefix = M01
ATC_suffix = AH03
PubChem = 119607
DrugBank = APRD00183
C = 16 | H = 14 | N = 2 | O = 3 | S = 1
molecular_weight = 314.364 g/mol
bioavailability = 83%
protein_bound = 98%
metabolism = Hepatic (CYP3A4 and 2C9 involved)
elimination_half-life = 8 to 11 hours
excretion = Renal
pregnancy_AU = C
pregnancy_category = May cause premature closure of theductus arteriosus
legal_status = Withdrawn in U.S., EU,Canada & parts ofAsia
routes_of_administration = OralValdecoxib is a prescription drug used in the treatment of
osteoarthritis ,rheumatoid arthritis , and painfulmenstruation and menstrual symptoms. It is classified as a nonsteroidal anti-inflammatory drug, orNSAID , and should not be taken by anyone allergic to these types of medications.Valdecoxib was manufactured and marketed under the brand name Bextra by
G. D. Searle & Company . It was approved by the United StatesFood and Drug Administration on November 20, 2001 [Thomson Micromedex. [http://www.micromedex.com/pressroom/news_feeds/fdaapprovals/fda_valdecoxib.html "Valdecoxib. U.S. FDA Drug Approval."] Last accessed June 8, 2007.] , and was available by prescription in tablet form until2005 , when it was removed from the market due to concerns about possible increased risk of heart attack andstroke .Uses
Since its registration, Bextra was prescribed for pain associated with
arthritis , menstrual discomfort, and other ailments.ide-effects and withdrawal
On April 7, 2005, Pfizer withdrew Bextra from the U.S. market on recommendation by the FDA, citing an increased risk of heart attack and
stroke and also the risk of a serious, sometimes fatal, skin reaction. This was a result of recent attention to prescription NSAIDs, such as Merck's Vioxx. Other reported side-effects were angina andStevens-Johnson syndrome .Pfizer first acknowledged cardiovascular risks associated with Bextra in October 2004. The American Heart Association soon after was presented with a report indicating patients using Bextra while recovering from heart surgery were 2.19 times more likely to suffer a stroke or heart attack than those taking placebos.
Recently in a large study published in JAMA 2006, valdecoxib appears less adverse for renal (kidney) disease and heart arrhythmia compared to Vioxx, however elevated renal risks were slightly suggested. [ [http://www.cox2drugreview.org "Adverse Effects of Cyclooxygenase-2 Inhibitors on Renal and Arrhythmia Events: Meta-Analysis of Randomized Trials", (JAMA 2006, by Zhang JJ, Ding EL, Song Y.).] ]
References
External links
* [http://www.fda.gov/cder/drug/InfoSheets/HCP/valdecoxibHCP.htm FDA Alert on Bextra withdrawal]
* [http://www.cox2drugreview.org Large systematic review of adverse renal and arrhythmia risk of valdcoxib and other COX-2 inhibitors, JAMA 2006]
Wikimedia Foundation. 2010.